Marwan Bahu, MD
Clinical Cardiac Electrophysiology · Phoenix, AZNPI 1114920618
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Biosense Webster, Inc. at 30.2% of the total. Reporting peaked in 2023 at $10,848 and has fallen 72.1% since, to $3,026 in 2025.
Across 497 payments — averaging $76.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$11K
- Boston Scientific$6K
- Cvrx, Inc.$6K
- GE HealthCare$5K
- Abbott$4K
- Medtronic$3K
- plus $3K from 16 others
Across 201 payments — averaging $8493.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biosense Webster, Inc.$525K
- Cvrx, Inc.$389K
- Boston Scientific$376K
- Medtronic$255K
- Medical Device Business Services, Inc.$95K
- Amarin Pharma, Inc.$35K
- plus $32K from 2 others
What the payments were for
- Consulting fees$9,13524%
- Speaking & faculty fees$6,80518%
- Travel & lodging$4,21811%
- Food & beverage$17,85647%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 277 | $11,473 |
| Boston Scientific | 47 | $6,166 |
| Cvrx, Inc. | 12 | $6,067 |
| GE HealthCare | 4 | $4,590 |
| Abbott | 66 | $4,085 |
| Medtronic(2 entities) | 54 | $2,859 |
| Volta Medical Inc | 7 | $1,382 |
| Atricure, Inc. | 6 | $347 |
| Biotronik Inc. | 3 | $326 |
| Abiomed | 2 | $261 |
| Cardiva Medical, Inc. | 5 | $133 |
| Penumbra, Inc. | 1 | $130 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Gilead | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Edwards Lifesciences | 1 | $24 |
| Novartis | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Elutia, Inc. | 1 | $12 |
| Altathera Pharmaceuticals LLC | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$5,659
- WATCHMAN Access System$4,411
- Carto 3$2,432
- AVEIR$1,224
- VX1$1,213
- Thermocool SF$794
- COBALT DR MRI SURESCAN$317
- Confirm Rx$290
- Impella$261
- Indigo$260
- Carto 3 System$242
- Quadra Assura CRT Defibrillator$225
- Micra$221
- AURORA EV-ICD MRI SURESCAN$166
- Arctic Front$158
- Quartet CRT Lead$158
- AMPLATZER Occluders$154
- GENERAL EP$146
- MitraClip$146
- QUADRA ASSURA$143
How this compares
$38,014 in reported general payments places this provider in the 55th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
See all clinical cardiac electrophysiology providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $297,475 |
| XareltoRivaroxaban | 106 | $144,448 |
| MultaqDronedarone Hcl | 24 | $28,808 |
| Dofetilide | 110 | $20,285 |
| EntrestoSacubitril/Valsartan | 13 | $18,620 |
| SotalolSotalol Hcl | 266 | $6,212 |
| Flecainide Acetate | 75 | $3,131 |
| Metoprolol Succinate | 94 | $1,320 |
| Potassium Chloride | 50 | $1,313 |
| Amiodarone Hcl | 50 | $1,292 |
| Amlodipine Besylate | 134 | $689 |
| Verapamil ErVerapamil Hcl | 17 | $588 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $587 |
| Warfarin Sodium | 26 | $459 |
| Atenolol | 25 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $24 | $144,448106 claims |
| NovartisEntresto | $22 | $18,62013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
Other clinical cardiac electrophysiology in Phoenix
- Akash MakkarPhoenix$318K
- Jonathan WeissPhoenix$290K
- Yoaav KrauthammerPhoenix$238K
- Vijendra SwarupPhoenix$187K
- Paul HaasPhoenix$136K
- Praneeth KatrapatiPhoenix$76K
- Komandoor SrivathsanPhoenix$57K
- Divyashree VarmaPhoenix$49K
- Sushmitha PatibandlaPhoenix$47K
- Mohamed AbdelrahmanPhoenix$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.